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Background: The burden of pneumonia continues to be substantial, particularly among the poorest in global
society. We describe here the trends for UK pneumonia R&D investment and published outputs, and correlate
with 2013 global mortality.
Methods: Data related to awards to UK institutions for pneumonia research from 1997 to 2013 were systemati-
cally sourced and categorised by disease area and type of science. Investment was compared to mortality ﬁgures
in 2010 and 2013 for pneumonia, tuberculosis and inﬂuenza. Investment was also compared to publication data.
Results: Of all infectious disease research between 2011 and 2013 (£917.0 million), £28.8 million (3.1%) was
for pneumonia. This was an absolute and proportionate increase from previous time periods. Translational
pneumonia research (33.3%) received increased funding compared with 1997–2010 where funding was almost
entirely preclinical (87.5%, here 30.9%), but high-burden areas such as paediatrics, elderly care and antimicrobial
resistance received little investment. Annual investment remains volatile; publication temporal trends show a
consistent increase. When comparing investment to global burden with a novel ‘investment by mortality
observed’metric, tuberculosis (£48.36) and inﬂuenza (£484.21) receive relativelymore funding than pneumonia
(£43.08), despite investment for pneumonia greatly increasing in 2013 compared to 2010 (£7.39). Limitations
include a lack of private sector data and the need for careful interpretation of the comparisons with burden,
plus categorisation is subjective.
Conclusions: There has been awelcome increase for pneumonia funding awarded toUK institutions in 2011–2013
compared with 1997–2010, along with increases for more translational research. Published outputs relating to
pneumonia rose steadily from 1997 to 2013. Investment relative to mortality for pneumonia has increased, but
it remains low compared to other respiratory infections and clear inequities remain. Analyses that measure
investments in pneumonia can provide an insight into funding trends and research gaps.
Research in context: Pneumonia continues to be a high-burden illness around the globe. This paper shows that
although research funding is increasing in the UK (between 1997 and 2013), it remains poorly funded compared
to other important respiratory infectious diseases such as tuberculosis and inﬂuenza. Publications about
pneumonia have been steadily increasing over time, indicating continuing academic and clinical interest in the
topic. Though global mortality of pneumonia is declining, it should still be an area of high priority for funders,
policymakers and researchers.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Despite documented complexities with epidemiological deﬁnitions
and clinical diagnosis (Scott et al., 2012), the global burden of pneumonia,
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including healthcare-associated and ventilator-associated pneumonia,
clearly remains signiﬁcant. Estimates from the Global Burden of Disease
Study 2013 (GBD 2013) suggested that although mortality from the
main pneumonia-causing pathogens was decreasing worldwide, there
were still at least 785,000 deaths globally from pneumococcal pneumo-
nia, respiratory syncytial virus and Haemophilus inﬂuenzae pneumonia
in 2013withmuch of this burden in low- andmiddle-income countries
(GBD 2013 Mortality and Causes of Death Collaborators, 2014),
although other analyses considered mortality to be greater (Kovacs
et al., 2015). In GBD 2013 ﬁgures, there were a further 105,000 deaths
from inﬂuenza, where pneumonia is a signiﬁcant secondary complica-
tion from primary infection, and an estimated 2 million deaths from
lower respiratory tract infections of unknown aetiology (GBD 2013
Mortality and Causes of Death Collaborators, 2014). The GBD study
also attributed 76.7 million disability-adjusted life-years (DALYs)
to pneumonia and pneumococcal disease in 2010, again with the
poorest sectors of society bearing the majority of this burden (Murray
et al., 2012). Though there is an increasing prevalence of non-
communicable disease and injuries in middle and lower-income
countries (GBD 2013 Mortality and Causes of Death Collaborators,
2014), projections from the World Health Organization (WHO)
estimate deaths from lower respiratory tract infections will remain
among the top 4 leading causes of deaths in 2015 and 2030 (World
Health Organization, 2013a).
Part of the solution to overcoming these challenges is to invest in
research. The UK is consistently rated among the top three investors
in neglected disease research (Policy Cures, 2014a), and UK-based
authors are generally proliﬁc at contributing to the published evidence
base (Yao et al., 2014). Thus the activity of UK institutions is likely to
be of signiﬁcant national and international importance. The Research
Investments in Global Health study (ResIn, www.researchinvestments.
org) has previously reported on infectious disease research investments
awarded to UK institutions between 1997 and 2010 (Head et al., 2013),
also speciﬁcally highlighting the limited and fractured nature of
pneumonia and pneumococcal research (Head et al., 2014a,b). There
is a paucity in the systematic tracking of global investments in health
research and development (R&D), with noted mismatches between
the global burden of pneumonia and research investment (Rudan
et al., 2011), and only one study of limited scope highlighting product
and technology-related R&D of bacterial pneumonia in low-income
settings (Policy Cures, 2014b).
We present an update to the ResIn study, covering awards for
pneumonia and pneumococcal-research from 2011 to 2013, with
reference to previously published data from 1997 to 2010 for context.
We highlight the trends in both total investment and temporal drift in
funding by type of science. Furthermore, we compare investment
against global mortality of disease and describe bibliometrics trends
for pneumonia-related publications as a surrogate of research output.
We discuss some clear challenges and evidence gaps, and review
potential ways forward.
2. Methods
Our methods for the analysis covering 1997–2010 are described in
detail elsewhere (Head et al., 2013, 2014b), and have been updated
for the 2011–2013 analyses.
2.1. Data collection
We systematically sourced information on funding decisions
from the major public and philanthropic funding bodies for infectious
disease research (http://researchinvestments.org/about-the-study/
study-methodology/). Private sector investment is not included due to
insufﬁcient information in the public domain. Data was obtained either
by searching online for the institution's portfolio of awards, or requested
directly from the funder.
2.2. Data categorisation and handling
The study team identiﬁed the infection-related awards led by a UK
institution and categorised them by disease area, by speciﬁc pathogen
and by type of science according to their position along the R&D value
chain. R&D categories were: preclinical research, phase I-III trials, inter-
vention and product development studies, translational (previously
referred to as implementation and operational research), and cross-
disciplinary awards. The cross-disciplinary category has been newly
created for the 2011–2013 analysis, reﬂecting the notable increase in
the number of studies with signiﬁcant components covering two
distinct types of science. We have not yet retrospectively applied this
new category to the 1997–2010 dataset though do not anticipate
revisions to greatly impact on observed trends in investment. Further
detail on data categorisation is available on the studywebsite, alongside
the full list of included funders and the search keywords used. Informa-
tion collected on each award included study title and abstract (where
available), the lead institution and principal investigator, funder, year
of award and total funding awarded. As per previous analyses (Head
et al., 2013), and similar to approaches recommended by others
(Young et al., 2015), awards originating from an international funder
were converted to UK pounds using the mean exchange rate in the
year of the award. All awards were adjusted for inﬂation and reported
in 2013 UK pounds.
Each study was categorised by author MGH. Awards for pneumonia
and pneumococcal-related research are included here. There were
random checks by at least two other individuals on 20% samples of
the data to reduce observer error, with differences reported and
corrected, and any remaining differences settled by consensus. Datasets
were also sent out to all authors for review and comment.
2.3. Data analysis
Burden data was sourced from the GBD study (GBD 2013 Mortality
and Causes of Death Collaborators, 2014; Lozano et al., 2012). UK invest-
ment and global mortality for pneumonia, tuberculosis and inﬂuenza
was analysed by comparing the sum funding across 2005–2009 with
2010 burden, and funding across 2008–2012 with 2013 burden.
Findingswere reported as an ‘investment bymortality observed’metric.
The datasetwas assembled inMicrosoft Excel 2013 and Stata (V13)was
used for further statistical analysis. Spearman's rank correlation coefﬁ-
cient (rho) was used to assess correlation.
2.4. Bibliometrics
The publications database Scopus® (http://www.scopus.com/) was
used to search for publications incorporating the keywords ‘pneumonia’
or ‘pneumococcal’, published between 1997 and 2013 and including at
least one author afﬁliated to a UK institution. Search results were
exported and conditional formatting equations used to identify papers
with a UK individual listed as ﬁrst or last author; this was a proxy
measure for signiﬁcant involvement from the UK and thus used to
compare with funding trends. Since most awards in our dataset are
either less than one year, or between two and three years in duration,
a likely publication yield for each year of investment was calculated by
using the total publications in the four years after the award, and this
produced an ‘investment per publication’ metric. Temporal trends,
citation numbers and type of publication were also considered.
Microsoft Excel 2013 and 2011 was used to assemble the bibliometrics
dataset, and Graphpad Prism 6 (http://www.graphpad.com/scientiﬁc-
software/prism/) produced the ﬁgures.
3. Results
Total research funding for all infectious diseases awarded to UK
institutions between 2011 and 2013 was £917.0 million across 1232
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awards (Table 1). Of this, £145.2 million (15.8%) and 219 awards
(17.8%)were related to respiratory infections. Pneumonia and pneumo-
coccal research received £28.8 million (3.1% of total and 19.9% of
respiratory infections funding) across 35 awards (2.8% of total and
16.0% of respiratory infections) (Table 1). By comparison across 2011–
2013, tuberculosis received £71.1 million (7.8% of total and 49.0% of
respiratory infections funding) from 83 awards (37.9% of respiratory
infections) and inﬂuenza received £39.1 million (4.3% of total and
26.9% of respiratory infections funding) across 53 awards (24.2% of
respiratory infections).
These ﬁndings represent an approximately three-fold total and
proportional increase from 1997 to 2010, where we reported that
pneumonia-related research represented 6.6% of all respiratory infec-
tions and 1.1% of all infectious disease research funding (Head et al.,
2014b). Total funding for pneumonia across the three-year period of
2011–2013 is greater than total funding across the fourteen year period
of 1997–2010, with mean annual pneumonia funding in this update
time period is £9.6 million compared with £2.0 million previously. The
mean annual number of awards has increased slightly from 7 to 12
and the median award size has increased from £137,389 to £335,210
(Interquartile range £196,000–642,463). Similarly, the total annual
investment in infectious disease research has increased by 64.6% in
the period 2011–2013, compared with 1997–2010, despite similar
numbers of awards. Investment and year were moderately correlated
(rho 0.6152, p = 0.0086), research output and year were strongly
correlated (rho 0.9798, p = 0.0001) and investment was moderately
correlated with research output (rho 0.6107, p = 0.0092).
Of the 35 pneumonia studies, 12 focused on Streptococcus
pneumoniae. Eight awards focused on vaccine research, with 3 awards
each concerned with diagnostics and therapeutics. Two awards had a
speciﬁc focus on paediatrics, with no awards focusing on elderly care.
Eight awards were clearly related to global health (Table 1). Temporal
trends, building on previously published data (Head et al., 2014a),
show an inconsistent long-term approach but signiﬁcant increases in
investment in recent years (Fig. 1).
Previously, Wellcome Trust was the leading funder of UK-awarded
pneumonia research (44.8% of the total 1997–2010, now 15.9%) (Head
et al., 2014b). In this update (Table 2), the European Commission
provided the largest proportion of pneumonia research investments
(31.2%) through 6 large awards, of which 5 were preclinical, amounting
to £9.2 million; during 1997–2010 they supported just two studies.
The second largest contribution was from the Bill & Melinda Gates
Foundation, which provided £7.4 million (26.6%) of investment across
5 awards, 4 of which were translational; during 1997–2010 there
were no awards from the Bill and Melinda Gates Foundation to UK
institutions for pneumonia.
There have been changes in pneumonia investment trends when
considering the type of science along the R&D pipeline. Previously,
87.5% of the funding was devoted to preclinical research (Head et al.,
2014a). Across 2011–2013 (Table 3, Fig. 2), preclinical research now
accounted 30.9% of investment, with comparable amounts awarded to
intervention andproduct development studies (32.7%) and translational
research (33.3%).
The ‘investment by mortality observed’ metric for pneumonia is
much greater in 2013 (£43.08) than 2010 (£7.39), though remains
less than tuberculosis (£48.36) and inﬂuenza (£484.21) across both
years (Table 4).
Therewere 8400 publications related to pneumonia that contained a
ﬁrst and/or last UK-afﬁliated author. Temporal trends show a steady
increase in publication numbers per year between 1997 and 2013
(Fig. 1), with the majority of publications being original articles (4771,
56.8%) or reviews (1759, 20.9%) (Fig. 3a). In 1997, there were 250
publications, and in 2013 there were 792, a more than three-fold
increase. The ‘R&D investment per publication’ metric demonstrated
great variability year on year, with a peak of £2395 in 2005 and a low
of £395 in 2007, and median investment across 1997–2009 of £779
per publication (Table 5). Citations of pneumonia publications included
in this dataset increased over time from 1997 (5874) until 2008
(16,862, an increase of almost three-fold) (Fig. 3b). For comparison,
equivalent median investment per publication for tuberculosis was
£6335 (range £1822–15,824), and £4100 (range £314–20,074) for
inﬂuenza. Tuberculosis publication numbers (8194) and temporal
trends were broadly similar to that of pneumonia, whilst inﬂuenza
publications (4864) and citationswere fewer butwith notable increases
around the timeof concerns around theH5N1 strain, and then theH1N1
pandemic strain (supplementary information).
4. Discussion
Annual pneumonia funding was considerably greater in the period
2011–2013 compared to the period 1997–2010, yet the increase in
number of awards remains modest with the pattern of investment
appearing to favour larger individual grants (a trend reﬂected across
all infectious disease research). There has been a notable shift in the
type of science funded, which previously was almost entirely devoted
to preclinical research but now represents a balance of preclinical,
intervention and product development, and translational research.
There are still relatively few studies funded by public and philanthropic
institutions that focus on tools to control pneumonia such as vaccines,
diagnostics and novel therapeutics, andminimal investment speciﬁcally
for paediatric, elderly care or antimicrobial resistance research.
The European Commission and Bill and Melinda Gates Foundation
are now the leading funders of pneumonia research awarded to UK
institutions (though the MRC and Wellcome Trust each contributed
the greater number of awards), highlighting an important shift in
funding policy and advocacy by global health organisations. Compared
to global mortality, pneumonia R&D funding is improving, as we
observe increased investment and decreased mortality. Tuberculosis
and inﬂuenza receive greater R&D investments in absolute terms and
also relative to their attributable burden of disease. Bibliometrics trends
for pneumonia show a broadly steady annual increase from 1997 to
2013, but with great variability when assessed using the ‘R&D invest-
ment per publication’ metric as applied here. The similar temporal
increase in citation numbers could be taken to indicate that one use of
the pneumonia publications is to continuously inform the development
of other published outputs, some of which will have resulted from the
funding analysed here; however, publications have variable impact
and further bibliometrics should be developed to evaluate use of
publications in informing other areas of knowledge such as policy
development. Linkage between individual investment and their
published outputs would be one area to develop to more closely map
the extent of any relationship between them.
The increase in investment in this high-burden and priority area is
clearly positive. It remains to be seen whether the trend of funding
consortia, programme grants and other large project grants, particularly
in areas of research beyond preclinical science, will reap the beneﬁts of
increased impact and ultimately provide a greater contribution to the
reduction of disease burden than has been observed so far. The burden
of pneumonia is decreasing, although it remains a focus of policy and
advocacy groups such as theWHO and Bill & Melinda Gates Foundation
(Bill and Melinda Gates Foundation, 2015; World Health Organization,
2013b), and accelerating the reductions in incidence will arguably
require a sustained increased level of investment in both research and
implementation. The lack of phase I-III clinical trials is concerning,
though this is an area where the private sector traditionally invests, at
least in high-income settings. Investments in innovative products with
the potential to impact on health would be a pragmatic approach for
future research, though the roll-out of research and any subsequent
implementation must be appropriate. The European and Developing
Countries Clinical Trials Partnership and the Global Fund have been
inﬂuential in this area in particular for HIV, tuberculosis and malaria.
Operational research is important to optimise the distribution and
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Table 1
Summary of investment information relating to infectious diseases and pneumonia research 2011–2013.
Disease 1997–2010 2011–2013
Number of
awards
Percentage of all
respiratory infection
or pneumonia
research
Total funding, £ Percentage of all
respiratory infection
or pneumonia
research
Number of awards Percentage of all
respiratory infection
or pneumonia
research
Total funding, £ Percentage of all
respiratory infection
or pneumonia
research
Mean award,
£ (SD)
Median award,
£ (IQR)
All Infectious disease 6165+ n/a 2,807,982,764+ n/a 1232 n/a 916,960,747 n/a 744,286
(1,360,777)
315,918
(156,283–779,794)
All respiratory infectious
disease
1010+ n/a 410,732,999+ n/a 219 n/a 145,182,110 662,932
(1,104,659)
319,019
(170,095–726,046)
Pneumonia 102+ 10.1% 27,788,770+ 6.8% 35 16.0% 28,849,125 19.9% 824,260
(1,340,046)
335,210
(196,000–642,463)
Pneumococcal 26 25.5% 4,417,895 15.9% 12 34.3% 8,944,883 31.0% 745,406
(1,207,254)
412,769
(261,084–647,062)
Disease areas and products⁎
Antimicrobial resistance 12 11.8% 2,899,479 10.4% 1 2.86% 4218 0.01% n/a n/a
Diagnostics 5 4.9% 335,993 1.2% 3 8.57% 6,814,845 23.62% 2,271,615
(3,624,003)
319,019
(42,617–6,453,209)
Geriatrics 1 1.0% 7933 0.0% 0 n/a 0 n/a n/a n/a
Global health 12 11.8% 4,626,308 16.6% 8 22.86% 17,437,921 60.45% 2,179,740
(2,241,692)
1,039,549
(598,711–3,651,835)
Healthcare-associated
infections
2 2.0% 313,651 1.1% 2 5.71% 361,636 1.25% n/a n/a
HIV 7 6.9% 1,397,599 5.0% 1 2.86% 404,523 1.40% n/a n/a
Paediatrics 9 8.8% 1,733,415 6.2% 2 5.71% 3,331,750 11.55% n/a n/a
Therapeutics 4 3.9% 1,050,241 3.8% 3 8.57% 1,166,680 4.04% 388,893
(235,729)
319,019
(196,000–651,661)
Vaccinology 9 8.8% 5,364,389 19.3% 8 22.86% 10,371,078 35.95% 1,296,385
(1,447,016)
604,472
(443,647–1,757,426)
⁎ Percentages in “disease areas and products” are calculated as a fraction of all pneumonia research rather than all respiratory infection research. Because awards can cover more than one disease area or product category, the sum of these column
percentages may exceed 100%.
+ Data published previously but here corrected for 2013 inﬂation (Head et al., 2013, 2014b).
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accessibility of pneumonia treatments such as antibiotics in the commu-
nity and oxygen in hospitals, as is the development of new vaccines to
protect against strains of pneumococcus not covered by the current
multivalent conjugate vaccines. The Bill & Melinda Gates Foundation
has invested signiﬁcantly in research to deﬁne the aetiology of pneumo-
nia in children in low-income countries over this period (Levine et al.,
2012). As GBD 2013 illustrates (GBD 2013 Mortality and Causes of
Death Collaborators, 2014), the large proportion of lower respiratory
tract infections with unknown aetiology remains a challenge for many
suffering from suspected pneumonia (Prendergast and Papenburg,
2013; Murdoch et al., 2012; Enne et al., 2014). Rapid point of care
tests demonstrating high speciﬁcity and sensitivity are urgently needed,
with a focus on products that are suitable for use in low-income
healthcare and community settings. Advances in nanotechnology
research may yield highly speciﬁc new assays (Howes et al., 2014);
however, they may emphasise the clinical uncertainty that identifying
the bacteria does not necessarily mean it is the pathogen causing the
illness (Enne et al., 2014). In terms of advocacy, building capacity and
attracting increased funding, there may be an opportunity to learn
from established research communities receiving proportionately
greater R&D investment, such as those who work on tuberculosis and
inﬂuenza. The area of pneumonia, though large, lacks a single-disease
advocacy body to focus attention on the likely returns on research
investments in this area. Elsewhere, a detailed analysis of research
priorities suggested that health policy and systems research to improve
Fig. 1. Sum research investment and publications for pneumonia, by year.
Table 2
Pneumonia research investments 2011–2013, by funder.
Disease Number of awards
2011–2013
Percentage
of total
Total funding
2011–2013
Percentage
of total
Mean award
£ (SD)
Median award
£ (IQR)
All pneumonia investment 35 £28,849,125 824,260
(1,340,046)
335,210
(196,000-642,463)
BBSRC 2 5.71% £1,060,870 3.68% n/a n/a
Bill and Melinda Gates Foundation 5 14.3% £7,360,368 25.51% 1,472,074
(1,767,709)
656,391
(603,102-1,422,707)
European Commission 6 17.1% £9,185,732 31.84% 1,530,955
(2,533,903)
188,121
(170,095-2,101,297)
Medical Research Council 9 25.7% £5,617,685 19.47% 624,187
(821,816)
273,432
(235,476-564,749)
National Institute for Health Research 2 5.71% £941,053 3.26% n/a n/a
Wellcome Trust 8 22.9% £4,592,214 15.92% 574,026
(622,481)
363,534
(302,855-485,644)
Other 3 8.57% £91,202 0.32% 30,400
(22,691)
42,617
(4218-44,367)
Table 3
Pneumonia research investments 2011–2013, by type of science.
Disease Number of awards
2011–2013
Percentage
of total
Total funding
2011–2013
Percentage
of total
Mean award
£ (SD)
Median award
£ (IQR)
All pneumonia investment 35 £28,849,125 824,260
(1,340,046)
335,210
(196,000-642,463)
Pre-clinical 22 62.9% £8,917,385 30.9% 405,335
(424,894)
280,062
(188,121-564,749)
Phase I-III 1 2.86% £554,959 1.92% n/a n/a
Intervention and product development 3 8.57% £9,426,000 32.7% 3,142,000
(3,144,551)
2776,792
(196,000-6,453,209)
Translational 8 22.9% £9,615,570 33.3% 1,201,946
(1,514,565)
530,457
(235,154-1,757,426)
Cross-disciplinary 1 2.86% £335,210 1.16% n/a n/a
Fig. 2. Proportion of research investment for pneumonia R&D, by year and by type of
science. * 1997–2010 data previously published (Head et al., 2014a).
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access and coverage by the existing interventions (such as vaccine and
therapeutic delivery) were key in the short term, as well as epidemio-
logical research to address the most important gaps in knowledge
(Rudan et al., 2011).
Antimicrobial resistance is anunder-resourced area across all invest-
ments for infectious disease research (Head et al., 2014c; Head, 2014),
and pneumonia is no exception. Globally, resistance to S. pneumoniae
is increasing. Recent trends have concerned the Centers for Disease
Control and Prevention (CDC) in the US who made speciﬁc reference
to this area in their unprecedented 2013 Threat Report (Centers for
Disease Control and Prevention, 2013), as well as being a focus of the
WHO 2014 global report on surveillance (World Health Organization,
2014). It is imperative to increase development in the R&D pipeline
of novel antibacterial therapies active major causes of pneumonia
including S. pneumoniae, Staphylococcus aureus, and Klebsiella
pneumoniae, especially those that are acquired in-hospital, where the
pathogens are highly selected for resistance. It is also important to
broaden the selection of agents to treat viral pneumonia, particularly
disease caused by inﬂuenza, para-inﬂuenza and respiratory syncytial
virus. The economic impact of infectious disease is notoriously difﬁcult
to quantify (Fonkwo, 2008), though the annual economic burden of
pneumonia in Europe has been estimated at €10.1 million (Welte
et al., 2012), and treating hospitalised cases of community-acquired
pneumonia in the US results inmean costs of $15,385 per patient across
over one million annual patient episodes (Sato et al., 2013).
There are recognised difﬁculties with any comprehensive analysis of
R&D data (Young et al., 2015), and the limitations of this study have
been described in detail previously (Head et al., 2013, 2014b). An
important point to reiterate here is the lack of private sector data.
Gaps in knowledge here will likely mask the true total investments
for, in particular, preclinical research and clinical trials for key advances
in vaccine, diagnostic and therapeutic development. There may also be
funds dedicated to respiratory infectious disease in any of the three
NIHR-funded Biomedical Research Units with a respiratory focus that
may not be listed as separate awards and thus not included here. We
do not take into account the proportion of each award dedicated to
each of the categories that may be applied to a single study. We also
do not investigate the distribution of funds from the lead institution to
any collaborating partners, nor do we take account of funding intended
for covering indirect or estate costs or any overheads. A basic sensitivity
Table 5
R&D investment for pneumonia and pneumonia-related published outputs.
Year Funding Publications Likely publication
yield
UK pound per
publication
1997 £611,493 250 1150 £532
1998 £1,794,230 250 1250 £1435
1999 £896,453 242 1463 £613
2000 £3,719,166 348 1581 £2352
2001 £1,264,689 310 1732 £730
2002 £1,332,194 350 1902 £700
2003 £1,853,285 455 1997 £928
2004 £239,056 466 2069 £116
2005 £5,431,788 461 2268 £2395
2006 £1,851,883 520 2376 £779
2007 £1,023,629 550 2591 £395
2008 £3,449,233 538 2868 £1203
2009 £5,389,863 660 3000 £1797
2010 £1,345,555 628 n/a n/a
2011 £9,763,953 765 n/a n/a
2012 £13,853,844 815 n/a n/a
2013 £5,231,327 792 n/a n/a
Table 4
Relationship between research investment andmortality for pneumonia, tuberculosis and
inﬂuenza.
Infection Year Numbers of
deaths
Investment 5 years
beforehand
R&D investment
per death
Pneumonia⁎ 2010 2,319,100 £17,146,396 £7.39
2013 784,600 £33,802,448 £43.08
Tuberculosis 2010 1,196,000 £86,338,770 £72.19
2013 1,290,300 £62,399,586 £48.36
Inﬂuenza 2010 507,900 £51,991,733 £102.37
2013 105,000 £50,841,831 £484.21
⁎ Pneumonia mortality data includes pneumococcal pneumonia/H. inﬂuenzae type b
pneumonia/respiratory syncytial virus pneumonia.
Fig. 3. a) Number of publications by year and publication type, b) number of citations, by year and publication type.
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analysis suggests that the Research Councils introduction of full
economic costing in 2004 has not greatly skewed the size of awards
and the volatility in total and temporal trends remainwhen considering
pneumonia funding with and without BBSRC and MRC data, though
there may be implications for other areas of infectious disease research.
The impact of the stochastic nature of research funding is also difﬁcult to
quantify. We rely on study titles and abstracts to provide speciﬁc men-
tion of pneumonia or alternatively clearly imply the study is related to
pneumonia. It is difﬁcult to quantify the level of funding missed in our
data collection exercise, however this is mitigated by the fact that all
major public and philanthropic funders of UK research, and dozens
more awarding bodies, have supplied data. The metric development
for investment bymortality and published outputs needs further devel-
opment and validation, and application to other disease areas to allow
direct comparisons.
Despite recent sum and relative increases, funding available for
pneumonia research remains disproportionately low, when compared
with the global burden of disease. There are no sustained comprehen-
sive efforts to track global pneumonia-related R&D investments, and
this should be tackled in order to allow simpler identiﬁcation of
research and evidence gaps. Other countries, particularly the US which
is the largest investor in global health, have pneumonia portfolios that
may cover areaswhere theUK is not investing. Amulti-country analysis,
similar to that carried out in the UK by the ResIn study, is warranted to
provide a comprehensive global investment surveillance system for
health R&D. A more detailed breakdown of bibliometrics trends and
linkage to investments data, plus identiﬁcation of additional measures
of research impact, across all infectious diseases and non-communicable
disease, would allow for greater scrutiny of how research investments
are allocated and how well they perform, openly assess accountability,
and ultimately allocate limited resources wisely.
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